Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079716 · ClinicalTrials.gov registry record · Phase 1
Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 5
- Study locations
NCT00079716: Completed Phase 1 study of Multiple Myeloma, sponsored by Seagen.
NCT00079716 is a Phase 1 study of Multiple Myeloma that has completed, run by Seagen. The registered enrollment target is 44 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00079716, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine the safety and activity of SGN-40 in a weekly dosage schedule as a single agent.
Conditions Studied
Interventions
- DRUG SGN-40 (anti-huCD40 mAb)
Study Locations (5)
California
- James R. Berenson M.D., Inc. - West Hollywood
Colorado
- Rocky Mountain Cancer Center - Denver
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Cornell University - New York
Ohio
- The Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2004-03 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
What the finished NCT00079716 record still lists
NCT00079716 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which SGN-40 (anti-huCD40 mAb) is the first listed.
NCT00079716 lists 5 locations in 5 states (California, Colorado, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00079716 about?
NCT00079716 is a clinical study titled "Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma". The purpose of this study is to determine the safety and activity of SGN-40 in a weekly dosage schedule as a single agent.
What is the current status of trial NCT00079716?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2004-03. Estimated completion is 2007-11.
What conditions does trial NCT00079716 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00079716?
The interventions under investigation include: SGN-40 (anti-huCD40 mAb) (DRUG).
Who is sponsoring clinical trial NCT00079716?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00079716 being conducted?
This trial has 5 study locations across California, Colorado, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00079716's enrollment target sits among peer trials
44 277th of 438 higher than 160 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia